Torrent Pharma acquires four brands from Dr Reddy's

27 May 2022

Ahmedabad, India-based Torrent Pharmaceuticals (BSE: 500420) has announced that it has entered into an agreement with Dr Reddy's Laboratories (BSE: 500124) to acquire four of its brands, namely Styptovit-E, Finast, Finast-T, and Dynapress.

Styptovit-E, a gynecology product with an estimated market size of ~Rs 500 crores (~$65 million) (AIOCD data set), will further strengthen Torrent’s presence in the therapy. The acquisition of Finast, Finast-T, and Dynapress, which are used in the treatment of benign prostatic hyperplasia (BPH), will aid in Torrent's presence in the urology therapy.

As per the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India. The complete integration and transition of the brands are expected to be completed by June 2022. Neither of the companies revealed financial terms of the transaction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK